PURA and KALY Announce Landing First Kenyan Coffee Shipment Adding to $8 Million 2020 Beverage Revenue Target

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Dallas, Texas--(Newsfile Corp. - December 3, 2019) - Puration, Inc. (OTC Pink: PURA) today announced the company has landed its first Kenyan coffee shipment. The company recently announced it will begin producing CBD infused Fair Trade coffee from Kenya. Now that the first shipment from Kenya has arrived, the company can begin formulating the CBD infusion. PURA has engaged Kali-Extracts, Inc. (OTC: KALY) to design the CBD infusion for ground coffee. KALY has a U.S. Patented Cannabis Extraction Process. PURA has the sole license of the patent for beverage infusion.

PURA currently makes and sells EVERx CBD Sports Water, the leading CBD sports drink in the sports nutrition market. PURA has recently confirmed a $4 million 2020 revenue target following the publication of its Q3 financial report. The company has also confirmed an $8 million 2020 revenue target built on the growing sales of EVERx and the introduction of new cannabis infused beverages.

A few months ago, PURA launched an initiative to partner with other beverage companies and introduce CBD Infused beer, coffee and tea beverages. PURA recently introduced TranquiliTeaCBD as its first new beverage from the beer, coffee and tea initiative. TranquiliTea is expected to be on shelves before the end of the year.

As part of PURA's new beverage initiative, PURA engaged Goldman Small Cap Research to conduct a CBD beverage industry survey (see link below). Goldman has published the final survey results of the survey.

CBD Beverage Survey Highlights

"Key Numbers: When asked in order of preference what CBD-infused beverage they would buy, 77 or 31% said tea and 74 or 30% said water. As a provider of water and tea, PURA leadership certainly is providing consumers the most popular categories of CBD-infused beverages which bodes very well for future sales and market share growth."

"The Trend is PURA's Friend: While CBD oils remain the most popular source of CBD products, the data and responses indicate that oils, vapes, and tinctures usage may be swapped on an ever-increasing scale, for edibles and beverages. We expect that they will eventually overtake these product categories which will be a boon to PURA."

To see the full final CBD Beverage industry survey results, follow the link below:
CBD Beverage Industry Results

For more information on Puration, visit http://www.purationinc.com.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/50350

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).